Therapeutics
-
Financial Markets
Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal
[ad_1] ZURICH (Reuters) -Switzerland’s Roche will acquire U.S. biopharma firm Poseida Therapeutics in a cash deal worth up to $1.5…
Read More » -
Financial Markets
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
[ad_1] On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March.…
Read More » -
Politics
23andMe lays off 40% of its workforce, ends therapeutics division
[ad_1] 23andMe is laying off 40 per cent of its workforce, or more than 200 employees, and discontinuing its therapeutics division…
Read More » -
Financial Markets
Why Intellia Therapeutics Stock Plummeted by 20% Today
[ad_1] Thursday was hardly a good day to be a shareholder of Intellia Therapeutics (NASDAQ: NTLA). After the biotech delivered…
Read More » -
Financial Markets
Jim Cramer Says ‘Hold On’ To Palantir, ‘Let Them Walk It Up’; Warns That Travere Therapeutics Is Losing A ‘Ton Of Money’
[ad_1] Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On CNBC’s…
Read More » -
Financial Markets
Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study
[ad_1] Investing.com — Shares of Intellia Therapeutics (NASDAQ:NTLA), Inc. took a nosedive today, dropping around 20% after the company announced…
Read More »
